The data for Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Italy shows a declining trend from 2024 to 2028, with anticipated cases decreasing from 59 to 55. Assuming the figures for 2023 were similar to 2024, this indicates a steady reduction in cases by approximately 1.7% each year over this period. This downward trend suggests effective public health interventions and improved treatment protocols.
Looking ahead, factors to monitor include:
- Potential emergence of new resistant TB strains.
- Changes in healthcare policies impacting TB diagnosis and treatment.
- Trends in international travel and migration affecting TB incidence.
- Innovations in TB vaccination and therapeutics.
